Literature DB >> 25083055

Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy.

Massimo Bellini1, Dario Gambaccini1, Cristina Stasi1, Maria Teresa Urbano1, Santino Marchi1, Paolo Usai-Satta1.   

Abstract

Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder in primary and secondary care. It is characterised by abdominal discomfort, pain and changes in bowel habits that can have a serious impact on the patient's quality of life. The pathophysiology of IBS is not yet completely clear. Genetic, immune, environmental, inflammatory, neurological and psychological factors, in addition to visceral hypersensitivity, can all play an important role, one that most likely involves the complex interactions between the gut and the brain (gut-brain axis). The diagnosis of IBS can only be made on the basis of the symptoms of the Rome III criteria. Because the probability of organic disease in patients fulfilling the IBS criteria is very low, a careful medical history is critical and should pay particular attention to the possible comorbidities. Nevertheless, the severity of the patient's symptoms or concerns sometimes compels the physician to perform useless and/or expensive diagnostic tests, transforming IBS into a diagnosis of exclusion. The presence of alarming symptoms (fever, weight loss, rectal bleeding, significant changes in blood chemistry), the presence of palpable abdominal masses, any recent onset of symptoms in patient aged over 50 years, the presence of symptoms at night, and a familial history of celiac disease, colorectal cancer and/or inflammatory bowel diseases all warrant investigation. Treatment strategies are based on the nature and severity of the symptoms, the degree of functional impairment of the bowel habits, and the presence of psychosocial disorders. This review examines and discusses the pathophysiological aspects and the diagnostic and therapeutic approaches available for patients with symptoms possibly related to IBS, pointing out controversial issues and the strengths and weaknesses of the current knowledge.

Entities:  

Keywords:  Diagnosis; Irritable bowel syndrome; Pathogenesis; Therapy

Mesh:

Year:  2014        PMID: 25083055      PMCID: PMC4112881          DOI: 10.3748/wjg.v20.i27.8807

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  110 in total

Review 1.  Clinical update: irritable bowel syndrome.

Authors:  Robin Spiller
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

2.  Irritable bowel syndrome: a multidimensional disorder cannot be understood or treated from a unidimensional perspective.

Authors:  Ami D Sperber; Douglas A Drossman
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

3.  Adequate relief as an endpoint in clinical trials in irritable bowel syndrome.

Authors:  A W Mangel; B A Hahn; A T Heath; A R Northcutt; S Kong; G E Dukes; D McSorley
Journal:  J Int Med Res       Date:  1998 Mar-Apr       Impact factor: 1.671

4.  The general practitioner's approach to irritable bowel syndrome: from intention to practice.

Authors:  M Bellini; C Tosetti; F Costa; S Biagi; C Stasi; A Del Punta; P Monicelli; M G Mumolo; A Ricchiuti; P Bruzzi; S Marchi
Journal:  Dig Liver Dis       Date:  2005-10-21       Impact factor: 4.088

5.  Quality of life in persons with irritable bowel syndrome: development and validation of a new measure.

Authors:  D L Patrick; D A Drossman; I O Frederick; J DiCesare; K L Puder
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

6.  Irritable bowel syndrome in twins: genes and environment.

Authors:  M-B Bengtson; T Rønning; M H Vatn; J R Harris
Journal:  Gut       Date:  2006-09-28       Impact factor: 23.059

7.  Self-perceived normality in defecation habits.

Authors:  M Bellini; P Alduini; G Bassotti; A Bove; R Bocchini; M P Sormani; P Bruzzi; F Pucciani
Journal:  Dig Liver Dis       Date:  2005-11-02       Impact factor: 4.088

8.  Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.

Authors:  Cesare Cremon; Luciana Gargano; Antonio M Morselli-Labate; Donatella Santini; Rosanna F Cogliandro; Roberto De Giorgio; Vincenzo Stanghellini; Roberto Corinaldesi; Giovanni Barbara
Journal:  Am J Gastroenterol       Date:  2009-01-13       Impact factor: 10.864

Review 9.  Is the irritable gut an inflamed gut?

Authors:  S M Collins
Journal:  Scand J Gastroenterol Suppl       Date:  1992

Review 10.  Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  A C Ford; N J Talley; P S Schoenfeld; E M M Quigley; P Moayyedi
Journal:  Gut       Date:  2008-11-10       Impact factor: 23.059

View more
  37 in total

1.  The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial.

Authors:  Octavian Alexea; Vlad Bacarea; Núria Piqué
Journal:  United European Gastroenterol J       Date:  2015-10-30       Impact factor: 4.623

2.  Gastrointestinal Symptoms in Women With Endometriosis and Microscopic Colitis in Comparison to Irritable Bowel Syndrome: A Cross-Sectional Study.

Authors:  Malin Ek; Bodil Roth; Mariette Bengtsson; Bodil Ohlsson
Journal:  Turk J Gastroenterol       Date:  2021-10       Impact factor: 1.852

3.  Translational Gap between Guidelines and Clinical Medicine: The Viewpoint of Italian General Practitioners in the Management of IBS.

Authors:  Massimo Bellini; Cesare Tosetti; Francesco Rettura; Riccardo Morganti; Christian Lambiase; Gabrio Bassotti; Pierfrancesco Visaggi; Andrea Pancetti; Edoardo Benedetto; Nicola de Bortoli; Paolo Usai-Satta; Rudi De Bastiani
Journal:  J Clin Med       Date:  2022-07-03       Impact factor: 4.964

4.  The Impact of Diagnostic Status on Quality of Life in Irritable Bowel Syndrome.

Authors:  Gillian Eleanor Cassar; George Youssef J; Simon R Knowles; Richard Moulding; David Austin
Journal:  Turk J Gastroenterol       Date:  2021-10       Impact factor: 1.555

5.  Patients with primary restless legs syndrome have higher prevalence of autonomic dysfunction and irritable bowel syndrome.

Authors:  Bilgehan Atılgan Acar; Mustafa Atahan Gürkan Acar; Türkan Acar; Ceyhun Varım; Aybala Neslihan Alagöz; Enis Bekir Demiryürek; Belma Doğan Güngen; Yeşim Güzey Aras
Journal:  Singapore Med J       Date:  2018-01-26       Impact factor: 1.858

Review 6.  Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules.

Authors:  Bryan L Copple; Tiangang Li
Journal:  Pharmacol Res       Date:  2015-12-17       Impact factor: 7.658

7.  Zeta Inhibitory Peptide as a Novel Therapy to Control Chronic Visceral Hypersensitivity in a Rat Model.

Authors:  Ying Tang; Aiqin Chen; Yu Chen; Lixia Guo; Hengfen Dai; Yang Huang; Qianqian Chen; Chun Lin
Journal:  PLoS One       Date:  2016-10-24       Impact factor: 3.240

Review 8.  Stem Cells in the Intestine: Possible Roles in Pathogenesis of Irritable Bowel Syndrome.

Authors:  Sutheera Ratanasirintrawoot; Nipan Israsena
Journal:  J Neurogastroenterol Motil       Date:  2016-07-30       Impact factor: 4.924

9.  Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial.

Authors:  Dorte Eskesen; Lillian Jespersen; Birgit Michelsen; Peter J Whorwell; Stefan Müller-Lissner; Cathrine M Morberg
Journal:  Br J Nutr       Date:  2015-09-18       Impact factor: 3.718

10.  Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.

Authors:  Natalia Zeber-Lubecka; Maria Kulecka; Filip Ambrozkiewicz; Agnieszka Paziewska; Krzysztof Goryca; Jakub Karczmarski; Tymon Rubel; Wojciech Wojtowicz; Piotr Mlynarz; Lukasz Marczak; Roman Tomecki; Michal Mikula; Jerzy Ostrowski
Journal:  Gut Microbes       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.